Allogene Therapeutics, Inc. Shares Issued
Allogene Therapeutics, Inc. (ALLO) had Shares Issued of 345.35 million shares as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Stockholders' Equity, Number of Shares, Par Value and Other Disclosure › Common Stock, Number of Shares, Par Value and Other Disclosure
us-gaap:CommonStockSharesIssued · last filed 2026-08-12
- 2026-06-30: Common Stock, Shares, Issued 345.35M shares.
- 2026-03-31: Common Stock, Shares, Issued 244.82M shares.
- 2025-12-31: Common Stock, Shares, Issued 229.41M shares.
- 2025-09-30: Common Stock, Shares, Issued 223.16M shares.
| Period end | Common Stock, Shares, Issued |
|---|---|
| 2026-06-30 | 345.35M shares 10-Q · filed 2026-08-12 |
| 2026-03-31 | 244.82M shares 10-Q · filed 2026-05-13 |
| 2025-12-31 | 229.41M shares 10-Q · filed 2026-08-12 |
| 2025-09-30 | 223.16M shares 10-Q · filed 2025-11-06 |
| 2025-06-30 | 220.13M shares 10-Q · filed 2025-08-13 |
| 2025-03-31 | 218.60M shares 10-Q · filed 2025-05-13 |
| 2024-12-31 | 212.21M shares 10-K · filed 2026-03-12 |
| 2024-09-30 | 209.50M shares 10-Q · filed 2024-11-07 |
| 2024-06-30 | 209.05M shares 10-Q · filed 2024-08-07 |
| 2024-03-31 | 170.45M shares 10-Q · filed 2024-05-13 |
| 2023-12-31 | 168.64M shares 10-K · filed 2025-03-13 |
| 2023-09-30 | 168.18M shares 10-K · filed 2024-03-14 |
| 2023-06-30 | 167.13M shares 10-K · filed 2024-03-14 |
| 2023-03-31 | 145.74M shares 10-K · filed 2024-03-14 |
| 2022-12-31 | 144.44M shares 10-K/A · filed 2024-03-14 |
| 2022-09-30 | 144.03M shares 10-K · filed 2024-03-14 |
| 2022-06-30 | 143.72M shares 10-K · filed 2024-03-14 |
| 2022-03-31 | 143.57M shares 10-K · filed 2024-03-14 |
| 2021-12-31 | 142.62M shares 10-K/A · filed 2024-03-14 |
| 2021-09-30 | 142.44M shares 10-Q · filed 2021-11-04 |
| 2021-06-30 | 142.12M shares 10-Q · filed 2021-08-04 |
| 2021-03-31 | 141.47M shares 10-Q · filed 2021-05-05 |
| 2020-12-31 | 140.47M shares 10-K · filed 2022-02-23 |
| 2020-09-30 | 139.76M shares 10-Q · filed 2020-11-04 |
| 2020-06-30 | 139.23M shares 10-Q · filed 2020-08-05 |
| 2020-03-31 | 125.26M shares 10-Q · filed 2020-05-06 |
| 2019-12-31 | 124.27M shares 10-K · filed 2021-02-25 |
| 2019-09-30 | 121.90M shares 10-Q · filed 2019-11-05 |
| 2019-06-30 | 121.63M shares 10-Q · filed 2019-08-07 |
| 2019-03-31 | 121.53M shares 10-Q · filed 2019-05-07 |
| 2018-12-31 | 121.48M shares 10-K · filed 2020-02-27 |
| 2018-09-30 | 31.27M shares 10-Q · filed 2018-11-21 |
| 2017-12-31 | 26.25M shares 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |